The Claim
In adults with type 2 diabetes and moderate-to-severe chronic kidney disease, weekly subcutaneous administration of 1.0 mg semaglutide for a median of 3.4 years reduces the risk of major kidney disease events—defined as kidney failure, a 50% or greater decline in estimated glomerular filtration rate, or death from kidney-related or cardiovascular causes—by 24% compared to placebo, with a hazard ratio of 0.76 (95% CI, 0.66 to 0.88; P=0.0003), indicating a clinically meaningful protective effect on renal and cardiovascular outcomes in this high-risk population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and moderate-to-severe chronic kidney disease, weekly injections of 1.0 mg semaglutide for about 3.4 years lower the risk of kidney failure, severe decline in kidney function, or death from kidney or heart causes by 24% compared to a placebo.
See the scientific wording
In adults with type 2 diabetes and moderate-to-severe chronic kidney disease, weekly subcutaneous administration of 1.0 mg semaglutide for a median of 3.4 years reduces the risk of major kidney disease events—defined as kidney failure, a 50% or greater decline in estimated glomerular filtration rate, or death from kidney-related or cardiovascular causes—by 24% compared to placebo, with a hazard ratio of 0.76 (95% CI, 0.66 to 0.88; P=0.0003), indicating a clinically meaningful protective effect on renal and cardiovascular outcomes in this high-risk population.
Semaglutide lowers blood sugar, which reduces damage to blood vessels in the kidneys and heart. It also lowers blood pressure and decreases inflammation, which protects the kidneys from further decline and prevents heart-related deaths.
What the research says
1 studyStudy: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
In people with type 2 diabetes and bad kidney disease, a weekly shot of semaglutide helped lower their chances of needing dialysis, having their kidneys get much worse, or dying from heart or kidney problems—by about a quarter over three years.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.